Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants
SARS-CoV-2 변이체에 대한 니르마트렐비르의 시험관내 효능에 대한 구조적 기초
Article
[키워드] Alpha
B.1.1.529
B.1.1.7
B.1.351
Beta
biochemical
catalytic activity
catalytically
cells
comparable
COVID-19 pandemic
crystal structure
Delta
Efficacy
enzymatic assay
enzyme
evaluated
Frequency
Gamma
in vitro
in vitro data
inhibitor
Ki
Lambda
M pro
M(pro)
maintain
molecular basis
mutant
Mutation
Nirmatrelvir
observation
omicron
Omicron variant
P.1
Paxlovid
PF-07321332
plasma concentration
plasma concentrations
potency
prevalent
protease
Protease inhibitor
provided
public health threat
required
Ritonavir
SARS-CoV-2
SARS-CoV-2 variant
SARS-CoV-2 variants
Tablet
tablets
the SARS-CoV-2
variant
variants
variants of concern
variants of interest
variants of SARS-CoV-2
VoC
VOCs
VOIs
Washington
wildtype
[DOI] 10.1016/j.jbc.2022.101972 PMC 바로가기 [Article Type] Article
[DOI] 10.1016/j.jbc.2022.101972 PMC 바로가기 [Article Type] Article